WOBURN, Mass.--(BUSINESS WIRE)--June 15, 2006--ArQule, Inc. (Nasdaq: ARQL - News) today announced data from two Phase 1b combination therapy trials, one with ARQ 501 and docetaxel and one with ARQ 501 and gemcitabine, that support previously announced findings demonstrating clinical tolerability, favorable pharmacokinetics and promising signs of anti-tumor activity in cancer patients with a range of advanced solid tumors who had failed prior treatments with chemotherapy.
